For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

UNITED THERAPEUTICS REPORTS
FIRST QUARTER 2002 FINANCIAL RESULTS

Quarterly Loss Reduced for Third Consecutive Quarter;
Advance Remodulin Purchase Orders Received

Conference Call Scheduled for Friday, May 10, 2002 at 9:00 a.m. E.T.

Silver Spring, MD, May 9, 2002: United Therapeutics Corporation (Nasdaq: UTHR) today announced financial results for the quarter ended March 31, 2002.

"We are pleased to report that United Therapeutics' net loss for the quarter ended March 31, 2002 fell for the third consecutive quarter in a row," said Fred Hadeed, United Therapeutics' Chief Financial Officer. "Additionally, United Therapeutics ended the quarter with $162.2 million of cash and marketable investments and practically no debt."

United Therapeutics also announced that it has received advance purchase orders from its two US distributors for approximately $9 million of Remodulin, infusion pumps and supplies, pending FDA approval. These orders reflect estimates of the amount of Remodulin that these distributors initially will require to provide for existing and new patients after approval and to build an inventory reserve. United Therapeutics expects that commercially labeled Remodulin will be available to the distributors at the time of FDA approval.

"We are especially pleased with the recent publication by Drs. Simonneau, Barst and the Treprostinil Study Group of our pivotal trial results in the *American Journal of Respiratory and Critical Care Medicine*," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The data reported in this article drives our excitement over the impending launch of Remodulin with our US partners, Priority HealthCare Corporation and Gentiva Health Services, upon FDA approval."

Revenues in the first quarter of 2002 were $1.4 million, consistent with revenues in the first quarter of 2001. The net loss in the first quarter of 2002 was $5.7 million, as compared with a net loss of $9.4 million in the first quarter of 2001. This represents a reduction in net loss of 39% largely due to lowered expenses for research and development and general and administrative programs.

Research and development expenses in the first quarter of 2002 were $4.5 million as compared to $8.5 million in the first quarter of 2001. The decrease resulted primarily from a decrease in expenses due to completed patient enrollment in United Therapeutics' prostacyclin analog clinical trials. General and administrative expenses in the first quarter of 2002 were $2.6 million as compared to $3.9 million in the first quarter of 2001. The decrease was due primarily to the elimination of goodwill amortization effective January 1, 2002 and certain nonrecurring expenses in 2001.

Sales and marketing expenses were $518,000 in the first quarter of 2002 as compared to $845,000 in the first quarter of 2001. The decrease in sales and marketing was due to a reduction in marketing expenses for arginine products. Cost of sales were $770,000 in the first quarter of 2002, consistent with cost of sales in the first quarter of 2001.

Interest income was $2.0 million in the first quarter of 2002 as compared to $3.3 million in the first quarter of 2001. This decrease was attributable to reductions in cash available for investing.

United Therapeutics will host a teleconference on May 10, 2002 at 9:00 a.m. Eastern Time to discuss first quarter results and related business. The teleconference is accessible by dialing 1-800-360-9865. A rebroadcast of the teleconference will be available for three days following the teleconference by dialing 1-800-428-6051 from the US, or by dialing 973-709-2089 internationally, and using access code 241913.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

Statements made in this press release about FDA regulatory approval of Remodulin and the availability of commercial drug are forward-looking statements subject to risks and uncertainties such as those described in United Therapeutics' reports on Form 10-K and Form 10-Q as filed with the Securities and Exchange Commission, including the 2001 Form 10-K. Actual results may differ materially from anticipated results.

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS DATA
(In thousands, except share and per share data)

	Three months ended March 31, 2002	Three months ended March 31, 2001
Revenues:		
Sales	$ 1,406	$ 1,263
Sales to affiliates	-	220
Total revenues	1,406	1,483
Operating expenses:		
Research and development	4,509	8,469
General and administrative	2,584	3,920
Sales and marketing	518	845
Cost of sales	770	805
Total operating expenses	8,381	14,039
Loss from operations	(6,975)	(12,556)
Other income (expense):		
Interest income	1,999	3,285
Interest expense	(34)	(39)
Equity loss in affiliate	(77)	(62)
Write-down of marketable investments	(538)	-
Other – net	(53)	(31)
Total other income, net	1,297	3,153
Net loss before income tax	(5,678)	(9,403)
Income tax	-	-
Net loss	$ (5,678)	$ (9,403)
Net loss per common share - basic and diluted	$ (0.28)	$ (0.46)
Weighted average number of common shares outstanding - basic and diluted	20,225,220	20,392,682

CONSOLIDATED BALANCE SHEET DATA
(In thousands)

	March 31, 2002
Cash, Cash Equivalents, and Marketable Investments	$162,212
Total Stockholders' Equity	$190,802
Total Assets	$202,198